文献速递产科母胎医学

埃索美拉唑治疗早产性子痫前期女性:随机安慰剂对照试验

Esomeprazole to treat women with preterm preeclampsia: a randomized placebo controlled trial.
PubMed 文献 · Am J Obstet Gynecol · 2018-07-26

在南非Tygerberg医院开展的双盲随机安慰剂对照试验,纳入早产性子痫前期(孕26周+0天至31周+6天)孕妇120例,随机分为每日40mg埃索美拉唑组(59例)和安慰剂组(60例)。主要结局为延长妊娠5天,结果显示两组从随机化到分娩的中位时间无显著差异(埃索美拉唑组11.4天 vs 安慰剂组8.3天,P=.31),埃索美拉唑未延长妊娠或降低循环sFlt-1浓度。

要点

  • 每日40mg埃索美拉唑未延长早产性子痫前期孕妇的妊娠时间。
  • 埃索美拉唑组无胎盘早剥,安慰剂组6例(10%)(P=.01,校正后P=.14)。
  • 埃索美拉唑及其代谢物在母血中可检测到,但在脐血中仅微量。

核心结论

  • 每日40mg埃索美拉唑未延长早产性子痫前期妊娠,也未降低循环可溶性fms样酪氨酸激酶1浓度。
  • 作者认为可能需要更高的母体循环药物水平才能产生临床效果。

研究设计与样本

  • 在南非Tygerberg医院开展的双盲随机安慰剂对照试验。
  • 纳入孕26周+0天至31周+6天的早产性子痫前期孕妇,随机分配至每日40mg埃索美拉唑组或安慰剂组。
  • 共招募120例参与者,1例因随机化错误被排除,最终埃索美拉唑组59例、安慰剂组60例。
  • 入组时中位孕周为29+4周。
  • 主要结局为延长妊娠5天;次要结局为母儿结局,并比较与子痫前期相关的内皮功能障碍循环标志物及进行药代动力学研究。

主要发现

  • 从随机化到分娩的中位时间:埃索美拉唑组11.4天(四分位距3.6-19.7天)vs 安慰剂组8.3天(四分位距3.8-19.6天),埃索美拉唑组延长3天(95%CI -2.9-8.8;P=.31)。
  • 胎盘早剥:埃索美拉唑组0例 vs 安慰剂组6例(10%)(P=.01,校正后P=.14)。
  • 其他母儿结局及内皮功能障碍标志物均无差异。
  • 接受埃索美拉唑治疗者母血中可检测到埃索美拉唑及其代谢物,脐血中仅微量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preterm preeclampsia has a high rate of fetal death or disability. There is no treatment to slow the disease, except delivery. Preclinical studies have identified proton pump inhibitors as a possible treatment. OBJECTIVE: The purpose of this study was to examine whether esomeprazole could prolong pregnancy in women who have received a diagnosis of preterm preeclampsia. STUDY DESIGN: We performed a double-blind, randomized controlled trial at Tygerberg Hospital in South Africa. Women with preterm preeclampsia (gestational age 26 weeks+0 days to 31 weeks+6 days) were assigned randomly to 40-mg daily esomeprazole or placebo. The primary outcome was a prolongation of gestation of 5 days. Secondary outcomes were maternal and neonatal outcomes. We compared circulating markers of endothelial dysfunction that was associated with preeclampsia and performed pharmacokinetic studies. RESULTS: Between January 2016 and April 2017, we recruited 120 participants. One participant was excluded because of incorrect randomization, which left 59 participants in the esomeprazole and 60 participants in the placebo group. Median gestational age at enrolment was 29+4 weeks gestation. There were no between-group differences in median time from randomization to delivery: 11.4 days (interquartile range, 3.6-19.7 days) in the esomeprazole group and 8.3 days (interquartile range, 3.8-19.6 days) in the placebo group (3 days longer in the esomeprazole arm; 95% confidence interval, -2.9-8.8; P=.31). There were no placental abruptions in the esomeprazole group and 6 (10%) in the placebo group (P=.01, P=.14 adjusted). There were no differences in other maternal or neonatal outcomes or markers of endothelial dysfunction. Esomeprazole and its metabolites were detected in maternal blood among those treated with esomeprazole, but only trace amounts in the umbilical cord blood. CONCLUSION: Daily esomeprazole (40 mg) did not prolong gestation in pregnancies with preterm preeclampsia or decrease circulating soluble fms-like tyrosine kinase 1 concentrations. Higher levels in the maternal circulation may be needed for clinical effect.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Cluver CA, Hannan NJ, van Papendorp E, et al. Esomeprazole to treat women with preterm preeclampsia: a randomized placebo controlled trial. Am J Obstet Gynecol. 2018. PMID: 30055127. doi:10.1016/j.ajog.2018.07.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。